<?xml version="1.0" encoding="UTF-8"?>
<iati-activities version="2.03">
 <iati-activity default-currency="USD" hierarchy="1" humanitarian="0" iati-activities:version="2.03" xml:lang="EN" xmlns:iati-activities="http://d-portal.org/xmlns/iati-activities">
  <iati-identifier>NO-BRC-917687811-CEPI_02</iati-identifier>
  <reporting-org ref="NO-BRC-917687811" type="30">
   <narrative xml:lang="EN">Coalition for Epidemic Preparedness innovations</narrative>
  </reporting-org>
  <title>
   <narrative xml:lang="EN">Research and development of vaccines</narrative>
  </title>
  <description type="2">
   <narrative xml:lang="EN">1)	PREPARE for known epidemic and pandemic threats: End the acute phase of the COVID-19 pandemic by ensuring equitable access to a portfolio of COVID-19 vaccines favourable for LMICs and validate enabling science programmes to accelerate COVID-19 vaccine candidate development. Accelerate the development of vaccines and other biologic countermeasures against known high- risk pathogens, continuing vaccine development towards licensure for priority pathogens with a clear unmet need where vaccines could have an impact. Reduce the risk of further coronavirus pandemics, using the acceleration in vaccine technologies and methods due to COVID-19 response, with the ultimate objective to develop a broadly protective Betacoronavirus vaccine.

2)	TRANSFORM the response to the next novel threat: Using vaccine prototypes and platform innovations to give us a head-start on other novel threats. Investing and scaling critical enabling sciences to further accelerate rapid vaccine development. Investing in innovations to ensure vaccine manufacturing is cheaper, faster, and closer to an outbreak.

3)	CONNECT to enhance and expand global collaboration: Secure financing for epidemic preparedness and response, connecting countries, industry, public &amp; private sectors from all over the world, and global health partners to develop vaccines and build commitment to preparedness and access. Improve coordination among key stakeholders to enable system readiness, driving for collaboration and solutions which will enable a faster system-wide response. Promote equitable access principles as the foundation of any effective global response.</narrative>
  </description>
  <description type="1">
   <narrative xml:lang="EN">CEPI&#x2019;s vision is a world in which epidemics and pandemics are no longer a threat to humanity. Going into the strategic period from 2022-2026, termed &#x201C;CEPI 2.0&#x201D;, CEPI aims to raise the bar to develop and scale vaccines and other promising biologic countermeasures even faster. The R&amp;D community has moved with unprecedented speed in response to COVID-19, developing biological interventions like vaccines and monoclonal antibodies in less than 12 months. While these achievements are historic, what the world needs to avert the consequences of future epidemics and pandemics are countermeasures developed even faster. CEPI&#x2019;s mission is to accelerate the development of vaccines and other biologic countermeasures against epidemic and pandemic threats so they can be accessible to all people in need. CEPI believes safe and effective vaccine in 100 days from the moment that a pathogen is sequenced and/ or the need for a vaccine is recognised to initial availability for use should be the aspiration. Over the strategic period, CEPI aims to invest USD 3.5 billion across three overall strategic objectives:</narrative>
  </description>
  <participating-org role="4" type="70">
   <narrative xml:lang="EN">Affinivax, Inc.</narrative>
  </participating-org>
  <participating-org role="4" type="80">
   <narrative xml:lang="EN">Aga Khan University</narrative>
  </participating-org>
  <participating-org role="4" type="70">
   <narrative xml:lang="EN">Aurobindo</narrative>
  </participating-org>
  <participating-org role="4" type="80">
   <narrative xml:lang="EN">BNITM</narrative>
  </participating-org>
  <participating-org role="4" type="80">
   <narrative xml:lang="EN">Benin FORS</narrative>
  </participating-org>
  <participating-org ref="DAC-1601" role="1" type="60">
   <narrative xml:lang="EN">Bill &amp; Melinda Gates Foundation</narrative>
  </participating-org>
  <participating-org role="4" type="70">
   <narrative xml:lang="EN">BioNet-Asia Co.,Ltd.</narrative>
  </participating-org>
  <participating-org role="4" type="70">
   <narrative xml:lang="EN">Clover Biopharmaceuticals</narrative>
  </participating-org>
  <participating-org role="4" type="80">
   <narrative xml:lang="EN">Colorado State University</narrative>
  </participating-org>
  <participating-org role="4" type="22">
   <narrative xml:lang="EN">Connected DMV</narrative>
  </participating-org>
  <participating-org role="4" type="70">
   <narrative xml:lang="EN">CureVac</narrative>
  </participating-org>
  <participating-org role="4" type="80">
   <narrative xml:lang="EN">Dalhousie Univesity</narrative>
  </participating-org>
  <participating-org role="4" type="15">
   <narrative xml:lang="EN">Defence Science and Technology Laboratory</narrative>
  </participating-org>
  <participating-org role="4" type="70">
   <narrative xml:lang="EN">Dynavax</narrative>
  </participating-org>
  <participating-org role="4" type="70">
   <narrative xml:lang="EN">Emergent BioSolutions</narrative>
  </participating-org>
  <participating-org role="4" type="22">
   <narrative xml:lang="EN">Epicentre</narrative>
  </participating-org>
  <participating-org role="1" type="90">
   <narrative xml:lang="EN">European Commission</narrative>
  </participating-org>
  <participating-org role="4" type="21">
   <narrative xml:lang="EN">FIND</narrative>
  </participating-org>
  <participating-org role="1" type="10">
   <narrative xml:lang="EN">Government of Australia</narrative>
  </participating-org>
  <participating-org role="1" type="10">
   <narrative xml:lang="EN">Government of Canada</narrative>
  </participating-org>
  <participating-org role="1" type="10">
   <narrative xml:lang="EN">Government of Ethiopia</narrative>
  </participating-org>
  <participating-org role="1" type="10">
   <narrative xml:lang="EN">Government of Finland</narrative>
  </participating-org>
  <participating-org role="1" type="10">
   <narrative xml:lang="EN">Government of Indonesia</narrative>
  </participating-org>
  <participating-org role="1" type="10">
   <narrative xml:lang="EN">Government of Japan</narrative>
  </participating-org>
  <participating-org role="1" type="10">
   <narrative xml:lang="EN">Government of Malaysia</narrative>
  </participating-org>
  <participating-org role="1" type="10">
   <narrative xml:lang="EN">Government of Mexico</narrative>
  </participating-org>
  <participating-org role="1" type="10">
   <narrative xml:lang="EN">Government of New Zealand</narrative>
  </participating-org>
  <participating-org role="1" type="10">
   <narrative xml:lang="EN">Government of Panama</narrative>
  </participating-org>
  <participating-org role="1" type="10">
   <narrative xml:lang="EN">Government of Switzerland</narrative>
  </participating-org>
  <participating-org role="4" type="70">
   <narrative xml:lang="EN">IDT biologica</narrative>
  </participating-org>
  <participating-org role="4" type="80">
   <narrative xml:lang="EN">Imperial College</narrative>
  </participating-org>
  <participating-org role="4" type="70">
   <narrative xml:lang="EN">Inovio Pharmaceuticals</narrative>
  </participating-org>
  <participating-org role="4" type="70">
   <narrative xml:lang="EN">Integrum</narrative>
  </participating-org>
  <participating-org role="4" type="21">
   <narrative xml:lang="EN">International AIDS Vaccine Initiative</narrative>
  </participating-org>
  <participating-org ref="XM-OCHA-4438" role="4" type="80">
   <narrative xml:lang="EN">International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b)</narrative>
  </participating-org>
  <participating-org role="4" type="21">
   <narrative xml:lang="EN">International Vaccines Institute</narrative>
  </participating-org>
  <participating-org role="4" type="70">
   <narrative xml:lang="EN">Janssen</narrative>
  </participating-org>
  <participating-org role="4" type="80">
   <narrative xml:lang="EN">LSHTM</narrative>
  </participating-org>
  <participating-org role="4" type="90">
   <narrative xml:lang="EN">Larissa</narrative>
  </participating-org>
  <participating-org role="4" type="70">
   <narrative xml:lang="EN">MERCK</narrative>
  </participating-org>
  <participating-org role="4" type="15">
   <narrative xml:lang="EN">Medicines and Healthcare products Regulatory Agency (MHRA)</narrative>
  </participating-org>
  <participating-org role="4" type="70">
   <narrative xml:lang="EN">Medigen Vaccine Biologics Corp.</narrative>
  </participating-org>
  <participating-org role="4" type="70">
   <narrative xml:lang="EN">MigVax Ltd</narrative>
  </participating-org>
  <participating-org role="4" type="15">
   <narrative xml:lang="EN">NIBSC</narrative>
  </participating-org>
  <participating-org role="4" type="80">
   <narrative xml:lang="EN">National Autonomous University of Mexico</narrative>
  </participating-org>
  <participating-org role="4" type="70">
   <narrative xml:lang="EN">Nexelis</narrative>
  </participating-org>
  <participating-org role="4" type="15">
   <narrative xml:lang="EN">Nigeria NCDC</narrative>
  </participating-org>
  <participating-org role="1" type="70">
   <narrative xml:lang="EN">Norstat Denmark</narrative>
  </participating-org>
  <participating-org role="1" type="70">
   <narrative xml:lang="EN">Norstat Norge</narrative>
  </participating-org>
  <participating-org role="4" type="70">
   <narrative xml:lang="EN">Nuova Ompi S.r.l</narrative>
  </participating-org>
  <participating-org role="4" type="70">
   <narrative xml:lang="EN">P-95</narrative>
  </participating-org>
  <participating-org ref="US-EIN-91-1157127" role="4" type="21">
   <narrative xml:lang="EN">PATH</narrative>
  </participating-org>
  <participating-org role="4" type="15">
   <narrative xml:lang="EN">Public Health England</narrative>
  </participating-org>
  <participating-org role="4" type="70">
   <narrative xml:lang="EN">Public Health Vaccines</narrative>
  </participating-org>
  <participating-org ref="KR-GOV-010" role="1" type="10">
   <narrative xml:lang="EN">Republic of Korea</narrative>
  </participating-org>
  <participating-org role="4" type="80">
   <narrative xml:lang="EN">Robert Koch Institute</narrative>
  </participating-org>
  <participating-org role="4" type="70">
   <narrative xml:lang="EN">Shanghai Zerun Biotechnology Co., Ltd.</narrative>
  </participating-org>
  <participating-org role="4" type="80">
   <narrative xml:lang="EN">THSTI</narrative>
  </participating-org>
  <participating-org role="4" type="22">
   <narrative xml:lang="EN">Taskforce for Global Health</narrative>
  </participating-org>
  <participating-org role="4" type="80">
   <narrative xml:lang="EN">Technical University of Mombasa</narrative>
  </participating-org>
  <participating-org role="1" type="10">
   <narrative xml:lang="EN">The Government of Austria</narrative>
  </participating-org>
  <participating-org role="1" type="10">
   <narrative xml:lang="EN">The Government of Germany</narrative>
  </participating-org>
  <participating-org role="1" type="10">
   <narrative xml:lang="EN">The Government of Italy</narrative>
  </participating-org>
  <participating-org role="1" type="10">
   <narrative xml:lang="EN">The Government of Norway</narrative>
  </participating-org>
  <participating-org role="1" type="10">
   <narrative xml:lang="EN">The Government of Singapore</narrative>
  </participating-org>
  <participating-org role="1" type="10">
   <narrative xml:lang="EN">The Government of Spain</narrative>
  </participating-org>
  <participating-org role="1" type="10">
   <narrative xml:lang="EN">The Government of the United Kingdom</narrative>
  </participating-org>
  <participating-org role="4" type="70">
   <narrative xml:lang="EN">Themis Bioscience</narrative>
  </participating-org>
  <participating-org role="4" type="80">
   <narrative xml:lang="EN">Tulane University</narrative>
  </participating-org>
  <participating-org ref="GB-GOV-10" role="4" type="10">
   <narrative xml:lang="EN">UK - Department of Health and Social Care (DHSC)</narrative>
  </participating-org>
  <participating-org ref="US-USAGOV" role="1" type="10">
   <narrative xml:lang="EN">United States</narrative>
  </participating-org>
  <participating-org role="4" type="80">
   <narrative xml:lang="EN">Universiti Malaya</narrative>
  </participating-org>
  <participating-org role="4" type="80">
   <narrative xml:lang="EN">University of Antwerpen</narrative>
  </participating-org>
  <participating-org role="4" type="80">
   <narrative xml:lang="EN">University of North-Carolina</narrative>
  </participating-org>
  <participating-org ref="GB-UKPRN-10007774" role="4" type="80">
   <narrative xml:lang="EN">University of Oxford, The</narrative>
  </participating-org>
  <participating-org role="4" type="80">
   <narrative xml:lang="EN">University of Pittsburgh</narrative>
  </participating-org>
  <participating-org role="4" type="80">
   <narrative xml:lang="EN">University of Queensland</narrative>
  </participating-org>
  <participating-org role="4" type="80">
   <narrative xml:lang="EN">University of Queensland</narrative>
  </participating-org>
  <participating-org role="4" type="80">
   <narrative xml:lang="EN">University of Tokyo</narrative>
  </participating-org>
  <participating-org role="4" type="80">
   <narrative xml:lang="EN">Universit&#xE9; Gamal Abdel Nasser de Conakry</narrative>
  </participating-org>
  <participating-org role="4" type="70">
   <narrative xml:lang="EN">VBI Vaccines Inc.</narrative>
  </participating-org>
  <participating-org role="4" type="70">
   <narrative xml:lang="EN">Valneva</narrative>
  </participating-org>
  <participating-org role="4" type="70">
   <narrative xml:lang="EN">Viroclinics Biosciences B.V</narrative>
  </participating-org>
  <participating-org ref="NL-KVK-09098104" role="4" type="80">
   <narrative xml:lang="EN">Wageningen University &amp; Research - Stichting Wageningen Research</narrative>
  </participating-org>
  <participating-org role="1" type="60">
   <narrative xml:lang="EN">Wellcome Trust</narrative>
  </participating-org>
  <participating-org role="4" type="70">
   <narrative xml:lang="EN">Zalgen Labs</narrative>
  </participating-org>
  <activity-status code="2"></activity-status>
  <activity-date iso-date="2016-08-30" type="2">
   <narrative xml:lang="EN">Company created in 2016. First disbursement to awardees made in 2018</narrative>
  </activity-date>
  <contact-info type="1">
   <organisation>
    <narrative xml:lang="EN">CEPI Secretariat</narrative>
   </organisation>
   <email>secretariat@cepi.net</email>
   <website>https://cepi.net/</website>
   <mailing-address>
    <narrative xml:lang="EN">Marcus Thranes gate 2, 0473 Oslo</narrative>
   </mailing-address>
  </contact-info>
  <activity-scope code="1"></activity-scope>
  <recipient-region code="998" percentage="100" vocabulary="1">
   <narrative xml:lang="EN">CEPI funds are invested in projects all over the globe. Allthough the companies that we fund may be located in HICs/MICs, the main benificiaries of the products we help develop will be developing countries.</narrative>
  </recipient-region>
  <sector code="12250" percentage="100" vocabulary="1"></sector>
  <default-flow-type code="10"></default-flow-type>
  <default-finance-type code="110"></default-finance-type>
  <default-aid-type code="B01" vocabulary="1"></default-aid-type>
  <default-tied-status code="5"></default-tied-status>
  <planned-disbursement type="1">
   <period-start iso-date="2022-01-01"></period-start>
   <period-end iso-date="2022-12-31"></period-end>
   <value currency="USD" value-date="2022-03-31">686700000</value>
  </planned-disbursement>
  <transaction>
   <transaction-type code="1"></transaction-type>
   <transaction-date iso-date="2022-03-31"></transaction-date>
   <value currency="USD" value-date="2022-03-31">1000000</value>
   <provider-org type="10">
    <narrative xml:lang="EN">Government of Malaysia</narrative>
   </provider-org>
  </transaction>
  <transaction>
   <transaction-type code="1"></transaction-type>
   <transaction-date iso-date="2022-03-31"></transaction-date>
   <value currency="USD" value-date="2022-03-31">3000000</value>
   <provider-org type="10">
    <narrative xml:lang="EN">Government of the Republic of Korea</narrative>
   </provider-org>
  </transaction>
  <transaction>
   <transaction-type code="1"></transaction-type>
   <transaction-date iso-date="2022-03-31"></transaction-date>
   <value currency="USD" value-date="2022-03-31">50000000</value>
   <provider-org type="10">
    <narrative xml:lang="EN">Government of the United States of America</narrative>
   </provider-org>
  </transaction>
  <transaction>
   <transaction-type code="1"></transaction-type>
   <transaction-date iso-date="2022-03-31"></transaction-date>
   <value currency="USD" value-date="2022-03-31">3013</value>
   <provider-org type="90">
    <narrative xml:lang="EN">Other investors</narrative>
   </provider-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2022-01-31"></transaction-date>
   <value currency="USD" value-date="2022-01-31">-18900000</value>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2022-02-28"></transaction-date>
   <value currency="USD" value-date="2022-02-28">69000000</value>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2022-03-31"></transaction-date>
   <value currency="USD" value-date="2022-03-31">13000000</value>
  </transaction>
  <document-link format="APPLICATION/PDF" url="https://cepi.net/wp-content/uploads/2022/01/CEPI-2_0-Programme-Doc-Jan21.pdf">
   <title>
    <narrative xml:lang="EN">CEPI 2.0 Programme document</narrative>
   </title>
   <category code="A02"></category>
   <language code="EN"></language>
   <document-date iso-date="2021-11-30"></document-date>
  </document-link>
  <document-link format="APPLICATION/APPLEFILE" url="https://aidstream.org/files/documents/Other-investors_as-of-March-31,-2022-20220422010424.pdf">
   <title>
    <narrative xml:lang="EN">Other investors</narrative>
   </title>
   <category code="B18"></category>
   <language code="EN"></language>
   <document-date iso-date="2022-03-31"></document-date>
  </document-link>
 </iati-activity>
</iati-activities>
